The ARIAD management team is the right mix of talent, expertise and experience to lead our company as we work to transform the lives of cancer patients with breakthrough medicines. In addition to people with proven scientific and medical backgrounds, our team includes seasoned individuals who know how to build and run a commercial business.
Paris Panayiotopoulos joined ARIAD in January 2016 as the Company’s President and Chief Executive Officer and member of its Board of Directors.
Mr. Panayiotopoulos comes to ARIAD from EMD Serono, Inc., where he most recently served as President, having joined its parent company Merck KGaA, Darmstadt, Germany in 2004. During his 11-year tenure there, Mr. Panayiotopoulos held positions of increasing responsibility. In addition to President of EMD Serono Inc, he also served as President of Merck Serono, Tokyo, Japan; Global Chief of Staff for the CEO in Geneva, Switzerland; Head of Western Europe for the Fertility and Endocrinology franchises; Global Director of the Neurology franchise; and Global Strategy and Business Intelligence Director.
Prior to joining Merck KGaA, Darmstadt, Germany, Mr. Panayiotopoulos was at Eli Lilly & Co. from 1999 to 2004.
Mr. Panayiotopoulos holds a combined BSc degree in Chemistry and Management Studies from University College London and an MSc degree in Marketing and Product Management from Cranfield Business School in the UK.
Daniel M. Bollag, Ph.D. has served as our Senior Vice President of Regulatory Affairs and Quality since January 2009. He previously served as Vice President, Regulatory Affairs, for Genzyme Corporation from 2006 to 2008.
From 2002 to 2006, Dr. Bollag held multiple positions at Sanofi-Aventis Pharmaceuticals, including Associate Vice President, Global Regulatory Domain Head, Associate Vice President, Global Regulatory Therapeutic Area Head, and Director, U.S. Regulatory Liaison. Dr. Bollag also served as Director, Project Planning and Management at the Bristol-Myers Squibb Pharmaceutical Research Institute from 2000 to 2002. Earlier in his career, from 1991-2000, he held positions at Merck Research Laboratories including Senior Project Manager, Project Planning and Management, Project Manager, and Senior Research Biochemist, Pharmacology.
Dr. Bollag completed a post-doctoral fellowship at Princeton University, and received his Ph.D. degree in Biochemistry from Cornell University. He earned his B.S. degree in Science and B.A. in French at Pennsylvania State University.
Maria E. Cantor has served as our Senior Vice President, Corporate Affairs since January 2012. Previously she served as our Vice President, Corporate Communications and Investor Relations since July 2008.
Prior to joining ARIAD, Ms. Cantor held several positions of increasing responsibility at Genzyme Corporation from 2001 to 2008, most recently serving as Senior Director, Corporate Communications. From 2000 to 2001, she held the position of Director, Public Relations and Marketing at St. Elizabeth’s Medical Center of Boston. From 1994 to 2000, Ms. Cantor held director positions in marketing and public relations at Optima Healthcare, Inc. and Catholic Medical Center. Prior to 1994, she was Assistant Press Secretary to former U.S. Congressman, Martin T. Meehan and served as News Anchor/Reporter at a Massachusetts broadcast station.
She received her M.S. degree in communications management from Syracuse University and her B.S. degree from Emerson College.
Timothy P. Clackson, Ph.D. has served as our President of Research and Development since June 2010 and our Senior Vice President and Chief Scientific Officer since September 2003. Previously, he served as our Senior Vice President, Science and Technology from June 2002 to September 2003, as our Vice President, Gene Therapy and Genomics from June 2000 to June 2002, as our Director, Gene Therapy from August 1999 to June 2000 and as our Department Head, Gene Therapy Biology from March 1999 to August 1999.
Prior to joining us in December 1994, Dr. Clackson was a postdoctoral fellow at Genentech, Inc., a biotechnology company, from 1991 to 1994, where he studied the molecular basis for human growth hormone function.
Dr. Clackson is on the Board of Directors of MassBio. He received his B.A. degree in Biochemistry from the University of Oxford. He received his Ph.D. degree in Biology from the University of Cambridge, for research conducted at the MRC Laboratory of Molecular Biology into antibody engineering and the development of phage display technology.
Hugh M. Cole joined ARIAD as Senior Vice President and Chief Business Officer in March 2014.
Prior to joining ARIAD, Mr. Cole held senior leadership roles in the rare disease business of Shire Pharmaceuticals, including Vice President of Business Development, Global Franchise Lead, and Senior Vice President, Strategy and Program Management. In his Business Development role, Mr. Cole led several in-licensing/acquisition transactions including the acquisition of Jerini AG. He also led the global development and launch of Firazyr, Shire’s market-leading product for acute attacks of hereditary angioedema. In his Strategy and Program Management role, Mr. Cole led a team of approximately 20 people, with responsibility for strategic planning, portfolio analysis, program management, and due diligence on external transaction opportunities. During Mr. Cole’s tenure at Shire, its rare disease revenue grew from approximately $300 million to over $1.5 billion.
Prior to joining Shire, Mr. Cole was Vice President of Corporate Development at Oscient Pharmaceuticals, where he completed several transactions, including product acquisitions/co-promotion deals that established a commercial revenue stream, as well as regional partnerships that generated upfront, milestone, and royalty payments. From 1998 to 2002, Mr. Cole held business development and planning positions at Millennium Pharmaceuticals and its affiliates.
Mr. Cole was a management consultant with The Wilkerson Group from 1992 to 1998 and began his career in 1987 as an investment analyst, covering biotechnology and pharmaceutical companies, with Fred Alger Management.
Mr. Cole earned a Bachelor of Arts in Chemistry from Harvard University in Cambridge, MA and his MBA in Health Care Management and Finance from the Wharton School in Philadelphia.
Martin J. Duvall was promoted to Executive Vice President and Chief Commercial Officer in December 2013, having joined ARIAD as our Senior Vice President, Commercial Operations in September 2011.
Prior to joining ARIAD, Mr. Duvall served as senior vice president and general manager of Merck and Company’s global oncology franchise. From 2009 to 2010, Mr. Duvall led global marketing and commercial operations at Abraxis Bioscience, Inc. From 2004 to 2009, Mr. Duvall held roles leading commercial operations, commercial development and oncology strategy for MGI Pharma, Inc. and its acquirer, Eisai. Earlier in his career, from 1986 to 2004, he held numerous oncology marketing and sales roles at Sanofi-Aventis and its predecessor companies, including a leadership role in the global development, commercialization and strategic direction of the company’s cytotoxic chemotherapy drugs.
He received a B.S. in Chemistry from Muhlenberg College, an M.A. in Chemistry from the Johns Hopkins University and an M.B.A from the University of Kansas.
Frank G. Haluska, M.D., Ph.D. has served as our Senior Vice President and Chief Medical Officer since January 2012, having held the position of Vice President and Chief Medical Officer since June 2010. Previously, he served as our Vice President, Clinical Affairs from May 2009 to June 2010, Vice President, Clinical Research from July 2008 to May 2009, and Senior Medical Director from October 2007 to July 2008.
Prior to joining ARIAD, Dr. Haluska served as a senior faculty member in the departments of medicine and genetics at Tufts University School of Medicine from 2005 to 2007, where he also was Clinical Director and Deputy Director of the Tufts-New England Medical Center Cancer Center. From 1994 to 2005, he held positions in academia, medical research and clinical oncology at centers of excellence, including assistant professor of medicine at Harvard Medical School, and leader of the melanoma research programs at Dana-Farber Cancer Institute (DFCI) and Massachusetts General Hospital (MGH) Cancer Center. Dr. Haluska is Colonel in the Medical Corps of the United States Air Force and the Massachusetts Air National Guard.
He completed a post-doctoral fellowship at MIT, fellowship training in medical oncology at DFCI, and his training in internal medicine at MGH. He received his M.D. and Ph.D. from the University of Pennsylvania School of Medicine and A.B. from Harvard University.
Manmeet S. Soni, joined ARIAD in March 2016 as the Company’s Executive Vice President, Chief Financial Officer and Treasurer.
Mr. Soni joined ARIAD from Pharmacyclics, where most recently he served as Chief Financial Officer until September 2015 having overall responsibility for finance, accounting, business development, procurement, IT, HR and commercial operations. Before taking over CFO responsibility at Pharmacyclics, he also served as Corporate Controller. Pharmacyclics was acquired by AbbVie, Inc. in May 2015. Prior to joining Pharmacyclics in 2012, Mr. Soni worked at ZELTIQ Aesthetics Inc., where he served as controller and senior director of finance. Mr. Soni began his career at PricewaterhouseCoopers, India in 2001 and then in 2007 moved to PricewaterhouseCoopers San Jose, in the Life Science and Venture Capital Group.
Mr. Soni currently serves on the board of Genoscience Pharma. He graduated from Hansraj College at Delhi University in India. He is a Certified Public Accountant, licensed in the State of California. He also completed his Chartered Accountancy from the Institute of Chartered Accountant of India.
Joseph Bratica has served as our Vice President, Finance and Controller since January 2005. Previously, he served as our Director of Finance and Controller from January 1999 to January 2005, Assistant Controller from January 1997 to December 1998 and as our Accounting Manager from August 1994 to December 1996.
Prior to joining us, he was Accounting Manager at Creative BioMolecules, Inc., a biotechnology company, from 1992 to 1994. Mr. Bratica received his B.A. degree in Accounting from Suffolk University.
David C. Dalgarno, Ph.D. has served as our Vice President, Research Technologies since September 2004. Previously, he served as our Vice President, Development Sciences from September 2003 to August 2004, Vice President, Physical and Chemical Sciences from November 1999 to September 2003, Director, Physical and Chemical Sciences from September 1998 to November 1999 and Director, Spectroscopy from October 1996 to August 1998.
Prior to joining us in March 1992, Dr. Dalgarno was a research scientist at Schering-Plough Corp. focusing on protein structure determination by nuclear magnetic resonance.
Dr. Dalgarno received his B.A. and Ph.D. degrees in Chemistry from the University of Oxford. He received his postdoctoral training in Molecular Biophysics and Biochemistry at Yale University.
Sean T. Daly has served as our Vice President, Clinical Operations since October 2015, and has led the execution of ARIAD’s clinical development programs since 2010. Previously, he served as our Senior Director of Clinical Operations from January 2013, having been promoted in January 2009 from the position of Director of Clinical Operations. He joined ARIAD in July 2004 as Senior Clinical Trial Manager and was promoted in January 2006 to Senior Manager of Clinical Operations.
Prior to joining ARIAD, Mr. Daly served as Clinical Trial Manager at Wyeth Research (formerly Genetics Institute), where he worked from November 1999 until June 2004 and held positions including Clinical Laboratory Liaison, Clinical Scientist and Clinical Trial Manager.
He previously worked at Agouron Pharmaceuticals as Assistant Librarian and at UCSD Medical Center Library as Serials Manager.
Mr. Daly earned a Bachelor of Science in Biochemistry and Cell Biology from the University of California at San Diego.
Jonathan E. Dickinson joined ARIAD as General Manager, ARIAD Pharmaceuticals (Europe), Sàrl, in February 2013. He was promoted to Senior Vice President and General Manager, Europe in October 2015.
Prior to joining ARIAD, Mr. Dickinson served as the European brand lead for ipilimumab at Bristol-Myers Squibb. Previously, during his 13-year tenure at Hoffmann-La Roche, Mr. Dickinson held several key leadership positions, including lifecycle leader for capecitabine. At Roche, he had assignments both in the United States and Switzerland that included leadership roles of Roche’s three leading oncology medicines—trastuzumab, rituximab and capecitabine. Mr. Dickinson began his career at Novartis, where he held commercial roles in its oncology and endocrinology businesses, including medical sales, product manager and business director in the United Kingdom.
Mr. Dickinson received his B.Sc. degree in Genetics and his M.B.A. degree from the University of Nottingham.
David Fritsche joined ARIAD as Vice President, Global Head of IT Clinical through Commercial in February 2016. He is responsible for the information systems supporting patient access to our treatments through the functions of clinical development, medical affairs, pharmacovigilance, and commercial operations.
Prior to joining ARIAD, Mr. Fritsche served as Sanofi’s Global IT Business Partner supporting scientific core platforms, including lead compound generation, pharmaceutical development, preclinical, and clinical. Prior to that, he co-led the data migration of all Genzyme and Sanofi-Pasteur safety data into the global Sanofi pharmacovigilance system.
Previously, Mr. Fritsche was with Genzyme for ten years before the Sanofi acquisition. Starting with EDC implementations for clinical trials and culminating with deployment of an industry-recognized platform for rare disease registries, he steadily gained responsibility to cover systems supporting clinical development, registration and post-marketing support.
Mr. Fritsche earned a B.A. in Computer Science from the University of Delaware and an M.B.A. in Marketing from the University of Rochester.
Shirish Hirani, Ph.D. has served as our Vice President, Drug Development since November 2013. Prior to that, he served as Vice President, Program and Alliance Management since January 2008. Previously, he served as our Vice President, Development Operations and Planning from October 2005 to January 2008.
From 2002 to 2005, Dr. Hirani served as Vice President, Program Management and as Vice President, Drug Development at Transkaryotic Therapies Inc., and from 1997 to 2002, he held various senior management positions at Dyax Corp., including most recently Senior Vice President, Product Development. Previously, Dr. Hirani held senior research and development positions at ImmuLogic Pharmaceuticals Corporation and Genzyme Corporation.
Dr. Hirani received his B.Sc and Ph.D. degrees in biochemistry from Queen Elizabeth College, University of London, United Kingdom.
Ronald K. Knickerbocker, Ph.D. joined ARIAD as our Vice President, Biomedical Data Sciences and Information, leading the biostatistics and data management functions, in February 2012.
Prior to joining ARIAD, Dr. Knickerbocker served as a Vice President at Genzyme Corporation from 2004 to 2012, where his positions included leading the biostatistics, data management and medical writing functions for the transplant/oncology business and global head of biostatistics and statistical programming. From 1999 to 2004, Dr. Knickerbocker was the statistical site head for Pfizer Inc. in Ann Arbor, MI. From 1993 to 1999, he held positions in Eli Lilly and Company, leading projects in women’s health and oncology.
He has a B.S. degree in Applied Mathematics and his M.S. and Ph.D. degrees in Statistics from Texas A&M University.
Timothy Maines joined ARIAD as Vice President, Quality, in March 2014.
Prior to joining ARIAD, Mr. Maines served as vice president of quality at Omthera Pharmaceuticals in Princeton, NJ. There, he was responsible for Quality and Technical GXP Operations from October 2001 until February 2014.
He previously held the vice president corporate quality assurance position at MedImmune, LLC, where from November 2007 to October 2011, he oversaw a 200 person QA Operations team at six GMP manufacturing facilities. From March 2000 to October 2007, Mr. Maines held various positions at GTC Biotherapeutics, including vice president of quality. Mr. Maines' experience also includes director of quality at Stryker Corporation-Biotech Division; director of quality assurance/quality control and manager of validation at Creative BioMolecules; and manager of quality assurance at BioProcess Technologies.
Mr. Maines earned a Bachelor of Science in Biology/Microbiology from Gannon University.
Yan Moore, M.D. joined ARIAD as Vice President, Medical Affairs, in April 2014.
Prior to joining ARIAD, from July 2011 until April 2014, Dr. Moore served as associate vice president of global medical affairs at Sanofi. There, he was responsible for Global Medical Affairs, clinical development and business opportunities for company’s gastro-intestinal and other solid tumor products.
He previously held the executive director of oncology clinical development position at GlaxoSmithKline from August 2009 to July 2011, where he focused on the clinical development for the lapatinib program. Dr. Moore joined GSK from Bristol Myers-Squibb, where from 2007 to 2009 he was the cetuximab development group director and a global GI cancer development lead across the oncology portfolio. Before joining BMS, Dr. Moore headed the Medical Affairs group at GPC biotech, Inc. with wide development responsibilities for the development of satraplatin for prostate cancer. Prior to GPC Biotech, he was the global medical director for Urology and GU oncology for GE Healthcare (ONCURA) from 2003 to 2006.
Dr. Moore earned a Bachelor of Science and M.D. degrees from the Sackler School of Medicine in Tel Aviv, Israel. He completed his internship in internal medicine at the Edith Wolfson Medical Center and a residency program in Ob/Gyn. He received his MBA from the LeBow College of Business at Drexel University in Philadelphia.
Christopher K. Murray, Ph.D. has served as our Vice President, Technical Operations since November 2013, leading the supply chain, manufacturing, development and Quality Control functions. Previously, he served as our Senior Director, Pharmaceutical Development from January 2011 to November 2013, as Senior Director, Manufacturing from January 2008 to December 2010 and Director, Manufacturing from November 2004 to December 2007.
Prior to joining ARIAD, Dr. Murray served as Director of API Materials at Allos Therapeutics, Inc. from March 2000 to November 2004. He began his career at Hauser Inc., where he held various management positions, including most recently Director, Chemical Processing Services.
Dr. Murray earned his B.S. in Chemistry at Hope College, and his Ph.D. in Organic Chemistry from the University of Chicago. He received his postdoctoral research training in Organic Chemistry at the University of Colorado, Boulder.
Narayana Narasimhan, Ph.D. has served as our Vice President, Drug Metabolism, Pharmacokinetics & Preclinical Safety since October 2015. Previously, he served as our Senior Director of the same department from January 2009 to September 2015 and Director of Drug Metabolism and Pharmacokinetics from September 2004 to December 2008.
Prior to joining ARIAD in September 2004, Dr. Narasimhan was a Principal Scientist at Bristol Myers Squibb working on the drug metabolism aspects of two drugs in development for hepatitis B and diabetes. Dr. Narasimhan started his pharmaceutical industry career at Merck & Co. as a Senior Research Chemist.
Dr. Narasimhan received his M.S. degree in chemistry from Indian Institute of Technology, India and a Ph.D. degree in Chemistry from Vanderbilt University. He received his postdoctoral training in Drug Metabolism at University of Kansas focusing on biotransformation, reactive intermediates and covalent binding.
Mark Organisak joined ARIAD in February 2013 and was promoted to Vice President, Tax & Treasury in October 2015.
Prior to ARIAD, he was Head of Partner Operations at The Boston Consulting Group, a global management consulting firm with 82 offices in 46 countries. From 2010 to 2012, he served as Senior Director for International Tax Planning at Covidien plc (now Medtronic), a medical devices company headquartered in Ireland, where he directed international transactional tax planning, corporate structuring and cross-border M&A.
Mark spent the majority of his career as an International Tax Partner with PricewaterhouseCoopers. During a 20 year career with Coopers & Lybrand and PwC that began in 1983, he worked in the Boston, Hong Kong, Tokyo and Pittsburgh offices. He worked with both start-up and evolving technology companies at all stages of development during his time in the Boston office. During his international assignments, he worked with the firm’s largest and most sophisticated clients, including United Technologies, Raytheon, Unilever and Philip Morris.
Mark has a BA in Political Science from Duquesne University, an MBA in Finance from the University of Pittsburgh, and a JD from the Duquesne University School of Law. He is a member of the American Institute of Certified Public Accountants and the American Bar Association's Tax Section.
Victor M. Rivera, Ph.D. has served as our Vice President, Preclinical and Translational Research since April 2009. Previously, he served in a variety of senior leadership positions including Senior Director, Biology from January 2007 to March 2009, Research Director from January 2003 to December 2006 and Principal Scientist from March 1999 to December 2002.
Dr. Rivera joined us in February 1993. He received his A.B. degree in Molecular Biology from Princeton University and his Ph.D. degree in Microbiology and Molecular Genetics from Harvard University. Dr. Rivera received his postdoctoral training in Signal Transduction at ARIAD.
Sergio Santillana, M.D.. M.Sc., joined ARIAD in March 2016 as Vice President, Clinical Research and Development.
Prior to joining ARIAD, Dr. Santillana worked as Senior Medical Director in Oncology Clinical Research at Takeda Oncology, where he was Global Clinical Lead in early development from 2014 to 2016. Previously, he held leadership positions at GlaxoSmithKline Oncology from 2006 to 2014, serving in R&D functions including Regional Therapeutic Area Head of Oncology and later Global Clinical Leader of one of the key targeted agents. He started his tenure in oncology drug development at Lilly Oncology from 2002 to 2006. Sergio brings a record of accomplishment, broad clinical experience, and deep industry knowledge to the Company.
Dr. Santillana earned his medical degree from the School of Medicine at Villareal University in Lima, Peru. Subsequently he trained at the Instituto Nacional de Enfermedades Neoplásicas (INEN), the National Cancer Institute of Peru. He later undertook additional training in bone marrow transplantation as a visiting fellow at St. Louis University. He spent his early career as a medical oncologist at INEN working in the clinic as well as in oncology clinical research and education, and recently earned an M.Sc. degree in experimental therapeutics from the University of Oxford in the UK.
William C. Shakespeare, Ph.D. has served as our Vice President, Drug Discovery since April 2009. Previously, he served as Senior Director, Chemistry from January 2007 to March 2009, Research Director from September 2004 to December 2006 and Principal Scientist from August 2000 to August 2004.
Prior to joining us in July 1996, Dr. Shakespeare was a Senior Research Scientist at Astra AB where he focused on CNS research. Dr. Shakespeare received his B.S. degree in Chemistry from Gettysburg College and his Ph.D. degree in Organic Chemistry from the University of New Hampshire. He received his postdoctoral training in Organic Chemistry at the University of Pennsylvania.
Andrew P. Slugg has served as our Vice President, Regulatory Affairs since October 2015, leading the Regulatory Liaison, Promotion Integrity, and Labeling functions. Previously he served as Senior Director, Regulatory Affairs from February 2013 to October 2015, and as Director, Regulatory Affairs from July 2011 to February 2013.
Prior to joining ARIAD, Andrew served as Director, Regulatory Affairs at Ipsen from May 2005 to July 2011 working in the areas of endocrinology, neurology, oncology, and hematology. He began his career at ORA Clinical Research and Development where, in addition to Regulatory Affairs, he held various management positions in Clinical Research and Quality Assurance.
Andrew holds a B.S. in Biology from Bates College (Lewiston, Maine), a Master of Science in Regulatory Affairs and Health Policy from The Massachusetts College of Pharmacy and Health Sciences (Boston), and a Master of Business Administration from the F.W. Olin Graduate School of Business at Babson College (Wellesley, Massachusetts).
Nicholas Ventresca joined ARIAD as Senior Vice President and Chief Information Officer in March 2015.
Prior to joining ARIAD, Mr. Ventresca was a management consultant engaged in the creation and implementation of multi-year strategic roadmaps at several Cambridge area biotechnology companies including Cubist Pharmaceuticals (now Merck), Paratek Pharmaceuticals, Epizyme and Bluebird Bio.
Prior to management consulting, Mr. Ventresca was Senior Vice President and Chief Information Officer at the Visiting Nurse Service of New York from September 2012 to March 2013. He held the position of Head of the Information Solutions (IS) Global Service for North America at Sanofi Corporation from July 2011 to August 2012 and CIO, Senior Vice President at Genzyme Corporation (now Sanofi) from May 2010 to June 2011. Mr. Ventresca has also served as CIO, Corporate Senior Vice President of Information Technology at Charles River Laboratories from March 2006 to April 2010. Mr. Ventresca has also held IT positions of growing responsibility at Pfizer from 1996 to 2006. Prior to Pfizer, Mr. Ventresca worked as CTO of Pepsi-Cola International and in senior positions at Custom Micro Concepts, S.G. Warburg & Co, and Drexel Burnham Lambert.
He received a B.S. in Biology from Fordham University and attended medical school in Rome, Italy.
Rickey Wilson, M.D., Esq., joined ARIAD as Vice President, Pharmacovigilance and Risk Management in November 2015.
Prior to joining ARIAD, Dr. Wilson served as acting Global Head of Pharmacovigilance at Sumitomo Dainippon Pharma, having moved from Vice President of Pharmacovigilance and Risk Management at Sunovion Pharmaceuticals to its parent company.
He previously held the postion of Director, Division of Epidemiology, Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research (CBER), at the U.S Food and Drug Administration (FDA) from May 2009 to March 2011.
Prior to FDA, Dr. Wilson held positions in industry, including Senior Vice President, Global Regulatory Affairs at Allergan, Inc., Vice President of Regulatory Affairs and Medical Vigilance at Baxter Healthcare, and several positions at business units of Johnson and Johnson, including the role of Senior Vice President of Drug Safety and Surveillance. Among many notable roles, Dr. Wilson served as Vice President of Corporate Regulatory Affairs at Pharmacia and Upjohn, Inc., as Vice President of Worldwide Regulatory Resources at E.R. Squibb and Sons (Bristol Myers Squibb) and Director of Clinical Drug Safety and Drug Regulatory Affairs at Boehringer Ingelheim Pharmaceuticals.
Dr. Wilson’s experience also includes serving as a Research Physician at the Department of Medical Oncology and Immunology at Hoffmann-La Roche, Director of the Health Department of Amarillo, Texas and Medical Epidemiologist at the Centers for Disease Control.
Dr. Wilson earned his B.A. from the University of Texas at Austin, his M.D., from the University of Texas Health Sciences Center at San Antonio, his MS in Epidemiology from Columbia University in New York, his JD from the University of San Francisco School of Law and his Masters of Medical Informatics from Northwestern University in Chicago.